 GAITHERSBURG, Md., Nov. 03, 2021 GLOBE NEWSWIRE -- NexImmune, Inc. Nasdaq: NEXI, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that two abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer SITC 36th Annual Meeting in Washington, D.C., being held November 10-14, 2021. 